UCL: uCloudlink Reports Sequential Improvement in Q1 as its Recovery Continues
By Lisa Thompson
NASDAQ:UCL
READ THE UCL RESEARCH REPORT
Akebia Therapeutics Stock Jumps as FDA Accepts Vadadustat US Application in CKD-Related Anemia
Akebia Therapeutics Inc (NASDAQ:AKBA) and its collaborator Otsuka Holdings (OTC:OTSKY) have announced that the FDA has accepted to review vadadustat’s marketing application for…
Immutep Announced New Collaboration with Merck KGaA, Darmstadt, Germany for LAG-3 Therapy, Efti
Immutep Limited (NASDAQ: IMMP) announces a new collaboration and supply agreement with Merck KGaA , Darmstadt, Germany (OTC: MKGAF) for a Phase I/IIa clinical trial in patients with solid tumours, calledINSIGHT-005.
Cathie Wood Buys $13.5M In Smart Glasses Supplier Vuzix On Dip
Cathie Wood-led Ark Investment Management bought 773,400 shares in Vuzix Corp (NASDAQ: VUZI) on Friday, estimated to be worth about $13.5 million.
The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes
After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May 28. Broader market sentiment and company-specific news flow dictated stock moves during the week.
Notable Insider Buys Of The Last Week: Bumble, Coty, Peloton Interactive, More
Insider buying can be an encouraging signal for potential investors, especially when markets are uncertain or near all-time highs.
Some return buyers were among the insiders acquiring shares this last week.
A beauty products company and an online dating outfit were among the firms that saw notable insider buying.
Cannabis Stock Gainers And Losers From May 28, 2021
GAINERS:
Canada House Wellness (OTC: SARSF) shares closed up 23.72% at $0.03
The Week In Cannabis: Stocks Trade Up On Federal Bill (MORE Act), Earnings, Big M&A
Cannabis stocks traded up this week, aided by strong earnings reports, big M&A announcements and the reintroduction of the Marijuana Opportunity Reinvestment and Expungement Act (MORE) into Congress, after the previous year's version failed to pass the Senate.